7:19 AM
 | 
May 17, 2018
 |  BC Extra  |  Clinical News

Jounce sags after ICOS mAb readout

Jounce Therapeutics Inc. (NASDAQ:JNCE) lost $6.22 (35%) to $11.45 Thursday after reporting data from the Phase I/II ICONIC trial evaluating the company's inducible T cell co-stimulator (ICOS) agonist mAb JTX-2011 to treat advanced solid tumors. The data were released late Wednesday in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

JTX-2011 as monotherapy led to one partial response (PR) in seven evaluable gastric cancer patients, for an overall response rate (ORR) of 14%. The therapy led to two cases of stable disease in five evaluable patients with triple-negative breast cancer (TNBC).

Given in combination with anti-PD-1 mAb Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY), JTX-2011 led to two PRs and two cases of stable disease in 19 evaluable patients with gastric cancer, for an ORR of 11%. The combo led to one PR in 15 evaluable patients with TNBC, for an ORR of 7%.

According to its U.S. label, PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) as monotherapy led to an ORR of 13%, including two complete responses and 17 PRs, in a Phase II trial in 143 gastric cancer patients.

Jounce said it has met its target enrollment in each of four combination cohorts of the trial in patients with gastric cancer, TNBC, squamous cell carcinoma of the head and neck (SCCHN) and non-small cell lung cancer (NSCLC).

Celgene Corp. (NASDAQ:CELG) has an exclusive option to to license multiple immuno-oncology programs from Jounce, including JTX-2011 (see BioCentury, Aug. 1, 2016).

Thursday's stock move shaved more than $200 million from Jounce's market cap, which slipped below $375 million.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD